Is Entrectinib developed by Roche?

Entrectinib (Entrectinib), this important anti-cancer drug, originated from the in-depth research and development of Roche. Its research and development history is quite legendary. It was originally started by the American company Ignyta. With the acquisition of Ignyta by Roche, the research and development results of entrectinib also naturally fell under Roche.

Entrectinib has emerged in the anti-cancer field with its unique mechanism of action. Not only can it be taken orally, it is also a selective inhibitor of the tyrosine kinase tropomyosin receptor kinase (Trk) A/B/C, c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK). It is particularly worth mentioning that it has the ability to cross the blood-brain barrier and has significant activity on the central nervous system (CNS). For those cancers that produce abnormal proteins due to NTRK gene fusion or ROS1 gene fusion, the active ingredients in entrectinib can precisely block the effects of these proteins, thereby curbing the unlimited proliferation of cancer cells and effectively slowing down the progression of cancer.

Sinceentrectinib has been approved for marketing in Japan, the United States and China since 2019, and its efficacy and safety have been widely recognized. It is widely used to treat various solid tumors containing NTRK1/2/3 or ROS1 gene fusions, bringing new hope to adult and pediatric patients with NTRK fusion-positive, advanced or recurrent solid tumors, as well as adult patients with ROS1-positive non-small cell lung cancer.

In the market, entrectinib is sold overseas under the brand nameRozlytrek, while in China it is known to the majority of patients as entrectinib capsules (Luo Shengquan/Rozlytrek). As the first ROS1 inhibitor in China with clear labeling of central nervous system efficacy, the launch of entrectinib undoubtedly provides a new and effective treatment option for patients with advanced non-small cell lung cancer.